Transaction · 0001193125-26-389514

Miralles Gines Diego

Miralles Gines Diego, PRES, HR, D, reported a transaction classified as grant at Artiva Biotherapeutics, Inc. involving 45000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 122500.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code APRES, HR, D
ARTVArtiva Biotherapeutics, Inc.
Trade date
Sep 09, 2026
Filing date
Sep 11, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded45.0k$0.00 per share
Holdings after122kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ARTV price since this filing

Daily closing prices, with the filing date and available return windows
ARTV · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +9.8%1w ago +10.7%1d ago +6.5%
Returns since7d -15.8%30d -32.1%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001193125-26-389514
Common Stock
Transaction date
Sep 09, 2026
Filed Sep 11, 2026, 10:37 PM · 2d delay
Shares
45,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
122,500 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • grant_or_award-22 points

    transaction_code = A

    Grant or award transactions are scheduled compensation, not discretionary.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & Head of R&D

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

  2. F2

    Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.

Original filing · 0001193125-26-389514
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ARTV